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Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly
active relapsing multiple sclerosis in Portugal
Bernardete Pinheiroa, Rita Guerreiroa, Jo~ao Costaa,b and Luıs Silva Miguela
aCentro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; bLaboratorio de
Farmacologia Clınica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
ABSTRACT
Aims: To assess the cost-utility of cladribine tablets versus fingolimod in patients with highly active
relapsing-remitting multiple sclerosis (RRMS) in Portugal.
Methods: A 1-year cycle cohort-based Markov state transition model was developed to simulate disease
progression, measured by Kurtzke Expanded Disability Status Scale (EDSS), relapses, and conversion to
secondary-progressive MS (SPMS). Patients were assumed to remain on treatment until progression to
EDSS level 7, conversion to SPMS, or complete loss of efficacy due to waning effect. Natural history was
based on British Columbia Multiple Sclerosis registry, London Ontario database, UK MS Trust, and cladri-
bine tablets clinical trial (CLARITY). Portuguese all-cause mortality was adjusted for the MS associated
increased mortality. Clinical inputs for active treatments (disability progression and relapse rate) were
estimated on a network meta-analysis. Utility weights were derived from UK-MS Survey and published
literature. Resource consumption by EDSS and due to relapses was based on published literature,
National DRG microdata and expert opinion. Unit costs were obtained from official sources. The analysis
was conducted from payers’ perspective, time horizon of 50 years and discount rate of 5%, for both
costs and benefits. Uncertainty was assessed via probabilistic and deterministic sensitivity analyses.
Results: Compared to fingolimod, cladribine tablets were associated with a delay in progression,
resulting in a gain of 0.85 quality adjusted life years (QALYs) and a cost decrease of 25,935 e.
Probabilistic sensitivity analysis resulted in a mean ICER of 31,781 e per QALY and was dominant in
98.7% of the simulations. Cladribine tablets were dominant across the scenario analyses tested.
Conclusions: Treatment of highly active RRMS with cladribine tablets was less costly and more effect-
ive than treatment with fingolimod. Hence, it is a dominant strategy in the Portuguese setting. No
conclusions can be drawn from the present study regarding other treatment options, in particular
natalizumab and alemtuzumab.
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Multiple sclerosis (MS) is an immune-mediated inflammatory
demyelinating disease of the central nervous system (CNS)
with loss of motor and sensory functions1. The incidence and
prevalence rates of MS vary substantially between geo-
graphic regions2. In Europe, the overall estimated incidence
and prevalence rates are 5.5 and 108 per 100,000, respect-
ively2. Lower estimations have been reported for Portugal
(4.48 and 56.20 per 100,000 for incidence and prevalence
rates, respectively)3,4. MS is twice as common in women as
men, with an average age of onset of about 30 years.
Disease progression is variable and influenced by both envir-
onmental and genetic factors5.
Different subtypes of MS have been identified, based on
clinical presentation and disease course. The most common
MS type is relapsing-remitting MS (RRMS; around 85% of MS
cases), which is characterized by clearly defined relapses
(attacks of new or increasing neurologic symptoms) followed
by remissions (periods of partial or complete recovery). By
definition, in RRMS there is no apparent progression of the
disease during remission. However, most RRMS cases will
eventually transit to another MS type designated secondary
progressive MS (SPMS), in which there is a progressive wor-
sening of neurologic function (accumulation of disability)
over time6,7. Patients with RRMS may be further classified as
having or not a highly active disease characterized by fre-
quent clinical relapses and/or magnetic resonance imaging
(MRI) activity, either when untreated or on a disease-modify-
ing drug (DMD)8. DMDs are indicated for most cases of
RRMS, with the aim of modifying disease progression, either
reducing the number of relapses or delaying the progression
of disability9,10. In RRMS, the current treatment options
include interferon-b, glatiramer acetate, natalizumab, fingoli-
mod, teriflunomide, alemtuzumab and dimethyl fumarate.
Second-line treatment with natalizumab, fingolimod or alem-
tuzumab is recommended to patients with active disease
and an insufficient response to at least one drug, as well as
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to patients with rapidly evolving severe RRMS11–14. In
Portugal, these second-line treatments are used in the treat-
ment of patients with highly active disease.
Cladribine tablets have recently been approved in Europe
for the treatment of adult patients with highly active RRMS
as defined by clinical or imaging features15. This decision
was based on the positive results from a large randomized,
double-blind, placebo-controlled clinical study (CLARITY)16,17
and its extension phase (CLARITY EXT)18. The recommended
dose of cladribine tablets is 3.50mg/kg over 2 years, adminis-
tered orally in one treatment course of 1.75mg/kg per year
(each treatment course comprises two treatment weeks dur-
ing the first 2 months).
The objective of this study is to estimate the cost-utility of
cladribine tablets compared to fingolimod in the treatment of
highly active RRMS in Portugal from the payer’s perspective.
Methods
Model structure
The analyses were conducted using an existing cohort-based
Markov model that simulated the costs and effectiveness of
RRMS treatment, following the structure used in previous
economic models19,20.
Disease progression was modelled using the Kurtzke’s
Expanded Disability Status Scale (EDSS) and comprises 21
states: 10 EDSS states for RRMS, 10 EDSS states for SPMS and
an all-cause death state (Figure 1). At each yearly cycle,
patients are at risk of experiencing disability progression
(moving to a higher EDSS state); improving in disability status
(moving to a lower EDSS state); remaining at their current
EDSS state; converting to SPMS with a simultaneous disability
progression; or die. Patients are assumed to remain on treat-
ment until progression to EDSS level 7, conversion to SPMS,
treatment discontinuation, or complete loss of efficacy due to
waning effect on disability progression and relapse rate. The
analysis assumed a time horizon of 50 years and a discount
rate of 5%, for both costs and benefits, as specified by the
Portuguese guidelines for the economic evaluation of
pharmaceuticals21.
Model inputs
The cohort considered in the model replicates the subgroup
of patients included in the CLARITY trial with high disease
activity (HDA), defined as: (a) at least one relapse in the pre-
vious year while on DMD and at least one T1 gadolinium-
enhancing lesion or at least nine T2 lesions, or (b) two or
more relapses in the previous year whether on DMD or not.
As observed in CLARITY trial, the mean age is 37.1 years and
the female to male ratio is 1.7. Table 1 shows the initial dis-
tribution amongst EDSS states.
Disease progression and relapse occurrence with either
treatment were modelled by applying a relative treatment
effect to the disease natural history. Assuming that the latter
represents what would occur if patients were on placebo,
this allows use of the results of a network meta-analysis that
compares the treatment effect of each DMD and placebo.
No prospective registry data for MS patients is available in
Portugal. Therefore, the disease natural history was based on
the British Columbia Multiple Sclerosis registry ([BCMS,
Canada]16). This registry includes a large representative MS
population, recording EDSS scores prospectively with a long-
term follow-up (28 years). In this research, transition probabil-
ities differ between those patients whose age at disease
onset are equal or greater, or less than 28 years old. Given
that the mean age at CLARITY baseline was 38 years old, the
Figure 1. Markov model.
Table 1. Initial HDA patient distribution, by EDSS state.
EDSS state
0 1 2 3 4 5 6 7 8 9
2.8% 2.8% 32.5% 21.5% 23.4% 11.1% 5.9% 0% 0% 0%
Abbreviations. HDA, high-disease activity; EDSS, expanded disability sta-
tus scale.
Source: EMD Serono, data on file.
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latter transition matrix was considered. Moreover, as the ori-
ginal BCMS analysis was performed on a cohort that covers a
broad group, including patients with mild and less progres-
sive forms of RRMS alongside people with highly active or
rapidly evolving disease, an acceleration factor that accounts
for a faster rate of progression on HDA population was
included. A hazard ratio (HR) of 1.38 was estimated by com-
paring the proportion of progression-free at week 96, for the
placebo arm, in the HDA-RRMS (71.7%) subgroup of CLARITY
with its complement (non HDA-RRMS, 78.6%). Due to the
lack of information by EDSS level, we assumed that the HR
was constant across all EDSS levels. The resulting annual
transition probabilities are shown in Table 2.
Besides EDSS transition, between RRMS health states,
patients were at risk of converting from RRMS to SPMS.
Annual transitions to SPMS, by EDSS RRMS state, were based
on the median time to event estimated using the London
Ontario registry23, as this registry allows estimation of a con-
version rate dependent on EDSS state. The annualized con-
version probabilities are shown in Table 3.
The transition progression matrix for SPMS based on data
from London Ontario is presented in Table 4.
The annualized relapse rate was obtained from the UK MS
Trust, which allows to estimate different relapse rates accord-
ing to EDDS state for both RRMS and SPMS24 (Table 5).
All-cause mortality rate, averaged by gender and age, was
derived from general population mortality reported in
national life tables25, and inflated by the authors of the
model20 to account for the excess mortality associated with
MS. The standardized mortality ratio by EDSS state was
modelled using data from a prospective survey of MS people
reported in Sadovnick et al. 26 and Pokorski27. The mortality
multiplier applied to both populations, RRMS and SPMS, is
showed in Table 6. The original study by Sadovnick et al.26
did not differentiate between MS subtypes. Therefore, we
assumed the same multiplier for both populations.
Comparative efficacy of cladribine tablets was obtained
from a systematic review and network meta-analysis
(NMA)28, which included aggregated data from 44 clinical tri-
als assessing 12 DMDs, and provided data for the subgroup
of patients with HDA. The clinical efficacy of DMDs in the
subgroup with HAD was modelled for the relative reduction
in annualized relapse rate (ARR) and a reduction in the haz-
ard rate for EDSS progression, defined as 3-month confirmed
disability progression. Although the original publication from
Siddiqui et al.28 presents only the results for the overall ITT
population and for confirmed disability progression at
6months, the technical report of the NMA (not published)
Table 2. Annual transition probability matrix by EDSS state (MS age of onset























0 60.5 26.3 9.4 2.8 0.5 0.2 0.2 0.0 0.0 0.0
1 5.8 61.8 20.7 8.0 2.2 0.6 0.8 0.1 0.0 0.0
2 1.6 12.1 52.9 22.0 5.8 2.4 2.8 0.2 0.1 0.0
3 0.6 5.0 12.0 45.9 11.9 7.6 15.2 1.3 0.5 0.0
4 0.2 2.2 6.7 11.5 39.9 13.5 21.8 3.3 0.9 0.1
5 0.1 0.5 2.9 5.9 8.7 39.2 35.2 5.0 2.4 0.1
6 0.0 0.1 0.4 2.5 3.1 4.1 68.8 14.6 5.9 0.6
7 0.0 0.0 0.1 0.2 0.7 0.4 11.7 69.3 16.1 1.6
8 0.0 0.0 0.0 0.0 0.1 0.1 1.9 5.6 90.3 2.1
9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 17.4 81.8
Abbreviations. EDSS, expanded disability status scale; HDA-RRMS, high disease
activity- relapsing remitting multiple sclerosis.
Source: Palace et al.22 and CLARITY trial.
Table 3. SPMS conversion probabilities, by EDSS state.












Abbreviations. EDSS, expanded disability status scale; SPMS,
secondary progressive multiple sclerosis.
Source: Ebers23.



















2 74.4 18.7 2.1 2.8 1.8 0.1 0.1 0.0
3 0.0 70.4 15.9 3.1 9.6 0.5 0.4 0.0
4 0.0 0.0 66.4 13.8 18.1 0.9 0.9 0.0
5 0.0 0.0 0.0 57.4 37.4 2.6 2.6 0.0
6 0.0 0.0 0.0 0.0 87.4 4.8 7.7 0.0
7 0.0 0.0 0.0 0.0 0.0 76.1 23.5 0.4
8 0.0 0.0 0.0 0.0 0.0 0.0 99.6 0.4
9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Abbreviations. EDSS, expanded disability status scale; SPMS, secondary pro-
gressive multiple sclerosis.
Source: Ebers23.
Table 5. Annualized relapse rate by EDSS state and MS classification.











Abbreviations. EDSS, expanded disability status scale; MS, multiple
sclerosis; RRMS, relapsing remitting multiple sclerosis; SPMS, second-
ary progressive multiple sclerosis.
Source: UK MS Trust30.
Table 6. MS standardised mortality ratios by
EDSS state.











Abbreviation. EDSS, expanded disability status scale.
Source: Sadovnick et al.26.
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and the model used provided data specifically for the HDA
subgroup and for the 3-month period. Table 7 shows the
results for the interventions assessed in the present study
(cladribine tablets and fingolimod).
The risk of treatment-related adverse events was based in
the systematic review and NMA28 and published literature29–31.
Waning effect assumptions were based on CLARITY and
the CLARITY extension study (CLARITY EXT) for cladribine
tablets, and NICE submissions for fingolimod32,33. According
to CLARITY EXT, treatment with cladribine tablets for two
years resulted in a durable clinical response for at least two
additional treatment-free years, with no significant differen-
ces in ARR or relapse-free proportion compared to the
response achieved at the end of CLARITY. Therefore it was
assumed that the full effect of cladribine tablets was
sustained through the first four years, waning from 66.7%
(fifth year) to 33.3% (sixth year) of drug effect, with no effect
assumed beyond year 6. For fingolimod, it was assumed
100% effect on the first 2 years, 75% from second year until
fifth year and 50% thereafter.
Annual probability of treatment withdrawal was estimated
based on CLARITY trial data for cladribine tablets (4.9%,
applied until 2 years of treatment) and based in the NMA28
for fingolimod (10.3%, applied while on treatment).
Adverse events were assumed to occur at the start of the
simulation. The list of adverse events was defined following
revision of the summary of product characteristics for each
drug. This information was validated by experts’ opinion. Model
inputs related to adverse events are presented on Table 10.
Utility scores
Utility weights for patients and caregivers, as well as the dis-
utility due to relapses, were derived from the UK MS Survey
and published literature34. The scores used in the model are
presented in Table 8. Adverse event disutility (ranging
between 0.110 and 0.400) and duration were obtained from
published literature35.
Resource utilization and costs
Resource consumption estimates were based on relevant
national published literature36. The estimates reported were
revised by clinical experts from the National MS society.
Hospital resource utilization and costs were directly sourced
from the Portuguese 2015 diagnostic related group (DRG)
microdata. Multiple sclerosis inpatient episodes were identi-
fied through International Classification of Diseases, 9th
Revision (ICD9: 340).
Resources were valued according to Portuguese official
sources: Portaria 234/201537 Catalogue for Public Health
Procurement (SPMS, 2016) and Infomed38. Only direct costs
were computed.
Table 9 presents the estimated annual costs by EDSS
state. In contrast with most previous cost-effectiveness analy-
ses on MS, the base-case scenario considered different costs
for relapse, according to EDSS state. The reason being
because the Portuguese experts consistently identified differ-
ent relapse resource consumption according to EDSS state
(including differences on the number of hospitalizations, on
rehabilitation and technical aids.
Cladribine tablets price was made available by the market
authorization holder. The dose depends on body weight
Table 7. Relative clinical efficacy of cladribine tablets and fingolimod,
vs. placebo.
Treatment related inputs Cladribine tablets Fingolimod
EDSS state progression
(HR vs. placebo)
0.281 (0.148–0.532) 0.620 (0.416–1.018)
Annualized relapse rate
(RR vs. placebo)
0.356 (0.242–0.506) 0.375 (0.269–0.507)
Abbreviations. EDSS, expanded disability status scale; HR, hazard ratio; RR,
rate ratio.
95% credible interval in parenthesis.
Table 10. Model inputs related to adverse events.
Event Probability of event Desutility per event27 One-off costs (e) Source of probabilities
Cladribine tablets (%) Fingolimod (%)
Progressive multifocal leukoencephalopathy 0.0 0.001 0.200 3,233 MS Trust (2016) e EMA24
Serious infection 2.8 2.2 0.190 1,917 NMA
Macular oedema 0.0 0.4 0.400 95 Pooled data
Gastrointestinal disorder 24.5 30.4 0.240 906 NMA
Thyroid related event 5.1 1.2 0.110 1,034 NMA
Influenza-like symptoms 1.3 0.5 0.210 16 NMA
Malignancy 0.6 0.6 0.116 5,290 Pakpoor et al. (2015)
Abbreviation. NMA, network meta-analysis.
Table 8. Mean utility scores.
Event Patients Caregivers
RRMS SPMS RRMS/SPMS
EDSS 0 0.870 0.045 0.002
EDSS 1 0.799 0.002
EDSS 2 0.705 0.002
EDSS 3 0.574 0.045
EDSS 4 0.610 0.142
EDSS 5 0.518 0.160
EDSS 6 0.460 0.173
EDSS 7 0.297 0.030
EDSS 8 0.049 0.095
EDSS 9 0.195 0.095
Relapse 0.071 0
Abbreviations. EDSS, expanded disability status scale; RRMS, relapsing remit-
ting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
Table 9. Estimated annual costs, by EDSS.






Abbreviation. EDSS, expanded disability status scale.
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(3.5mg/Kg), so drug costs were estimated according to the
weight distribution published in the Portuguese National
Health Survey 201425,39. Both cladribine tablets and fingoli-
mod are oral treatments, therefore no administration costs
were considered.
Costs associated with rescue therapy among cladribine-
treated patients were considered in the model as one-off
cost. A logistic-regression model with fixed effects for trial
group and region was adjusted to estimate the probability
of receiving rescue therapy for cladribine tablets versus pla-
cebo (OR ¼ 0.40 [0.19–0.81]). It was estimated that rescue
therapy with interferon beta-1a was given to 2.6% of
patients in cladribine arm.
Costs associated with treatment-related adverse events
are presented in Table 10.
Sensitivity analysis
Deterministic and probabilistic sensitivity analyses were per-
formed. One-way deterministic sensitivity analyses were
undertaken on the following parameters: transition probabil-
ities, mortality risk, discontinuation, treatment waning effect,
utility weights, discount rate, time horizon and costs (EDSS
disability, relapse and adverse events). For costs and utility
weights parameters, the deterministic sensitivity analyses
considered the estimates for Portugal40 from the recent
cross-sectional study41, conducted in 16 European countries.
A total of 535 Portuguese patients (54% with RRMS) were
included in the European cross-sectional study.
Probabilistic sensitivity analysis (PSA) was performed to
account for uncertainty in the estimate of the parameters.
The simulation included 10,000 iterations. The parameters
considered in the PSA and the corresponding distributions
are described in Table 11.
Results
Base-case scenario
Treatment with cladribine tablets was associated with a delay
in disease progression, resulting in a gain of 0.85 quality
adjusted life years (QALYs). From an economic viewpoint,
this delay allowed for a decrease in total follow-up costs that
amount to 25,935 e (time-horizon of 50 years). Paradoxically,
as the relative relapse risk was higher in lower EDSS states, it
implies an increase in relapse costs. These results showed
that cladribine tablets was dominant when compared to fin-
golimod (Table 12).
Sensitivity analysis
The sensitive analysis performed (Table 13) showed that
base-case results were robust, with cladribine tablets remain-
ing a dominant strategy compared to fingolimod.
All the assumptions regarding costs had a minor impact
on results. Considering an 11-state model, without distinction
between RRMS and SPMS, resulted in higher cost savings.
Although CLARITY EXT trial supports the durability of
cladribine tablets effect, if we assume that treatment effect
doesn’t sustain after the third year (worst case scenario), the
dominance was maintained.
Probabilistic sensitivity analysis resulted in a mean ICER of
31,781 e per QALY. These results confirmed the dominant
profile of cladribine tablets compared to fingolimod.
Cladribine tablets was dominant in 98.7% of the 10,000 simu-
lations (Figure 2).
Discussion and conclusion
In spite of the low incidence and prevalence rates, MS is one
of the leading causes of non-traumatic disability in young
adults (World Health Organization [WHO] 2013). Interestingly,
the global MS burden of disease, assessed by disability-
adjusted life years (DALY), has been recently reported to
have a global downward trend43. This trend was found for
both developed and developing countries, although MS
DALY rates are about 25 higher in developed countries com-
pared to developing ones. According to the authors, the rea-
son for this decline, especially in European countries, was
that by increasing level of health care (and budget) for MS
Table 11. Parameters and distributions used in probabilistic sensitiv-
ity analysis.
Parameters Distribution
Mean initial age Lognormal
Number of relapses on previous year Lognormal
Weight distribution Dirichlet
EDSS initial distribution Dirichlet
Mortality rate Lognormal
Annualized relapse rate Lognormal
Proportion of patients with rescue therapy Beta
Transition probabilities for SPMS Dirichlet
Transition probabilities for RRMS Dirichlet
HDA adjustment factor Lognormal
Progression risk (HR vs. placebo) Lognormal
Relapse rate (RR vs. placebo) Lognormal
Rescue therapy risk (OR vs. placebo) Lognormal
Withdraw risk Beta
Adverse events risk Beta
RRMS utility decrements Lognormal
SPMS utility decrement Lognormal
Utility decrement for caregivers RRMS/SPMS Lognormal
Utility decrement by relapse/adverse events Lognormal
Adverse events costs Lognormal
Costs by EDSS state/relapse Gamma
Salvage therapy duration Normal
Abbreviations. EDSS, expanded disability status scale; HDA, high-disease activ-
ity; HR, hazard ratio; RR, rate ratio; OR, odds ratio; RRMS, relapsing remitting
multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
Table 12. Results for estimated costs and consequences (base-case scenario).
Cladribine tablets Fingolimod Incremental
Total costs (e) 190,076e 216,012e 225,935e
Treatment 49,779e 65,985e 216,206e
Administration 0e 20e 220e
Monitoring 244e 478e 2234e
EDSS 129,207e 139,445e 210,238e
Relapse 9,947e 9,720e 227e
Rescue therapy 536e 0e 536e
Adverse events 363e 364e 0e
QALY 3.42 2.58 0.85
ICUR (e/QALY) 230,651e/QALY
Abbreviations. QALY, Quality adjusted life years; ICUR, incremental cost-util-
ity ratio.
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patients, the age of death had risen significantly in recent
years. Overall, this positive effect outweighs the negative
impact on the number of years that MS patients live
with disability.
Our study showed that cladribine tablets was a dominant
strategy in patients with HDA-RRMS, being a less costly and
more effective treatment than fingolimod. Cladribine tablets
demonstrated to have an incremental benefit on disease pro-
gression when compared to fingolimod. However, this bene-
fit was not observed when relapse rate was considered,
possibly due to the fact that estimated relapse rates were
lower in higher EDSS states.












Sa et al.40 25,742 0.85




Sa et al.40 28,081 0.85
Health-related quality of life
Hawton et al.42 25,935 0.79
Sa et al.40 – Portuguese tariffs 25,935 0.81
Without disutility by adverse events 25,935 0.85
Without caregivers’ disutility 25,935 0.80
No adverse events 25,935 0.85
11-state model structure 55,006 0.84
Progression based on London Ontario data 22,343 0.62
Without HDA subgroup adjustment 28,603 0.74
RRMS transition by disease duration 47,786 0.85
Relapse rate by disease duration 26,464 0.85
Fixed mortality (HR ¼1.68) 27,303 0.88
Discontinuation
No discontinuation 36,075 0.81
Same probability of treatment withdrawal for both arms (4.9%) 31,288 0.79
Waning effect
No cladribine tablets effect after third year 20,920 0.44
No cladribine tablets effect after second year 17,485 0.17
Assume the same waning effect of fingolimod for cladribine tablets 29,079 1.12
Assume the same waning effect of cladribine tablets for fingolimod (full efficacy for 4 years) 25,749 0.80








Abbreviations. QALY, Quality adjusted life years; EDSS, expanded disability status scale; HDA, high-disease activity; HR, hazard ratio.
Figure 2. Cost-effectiveness scatter plot.
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Our study had several limitations. First, this study does
not include other current treatment options for MS patients
with HAD, in particular natalizumab and alemtuzumab. The
reasons for not having included these comparators are: (1)
Fingolimod is the first treatment option in Portugal for MS
patients with HAD, representing about 2/3 of the overall
second-line treatments; (2) Alemtuzumab was not an option
at the time of the study (Q1, 2018) because it was not reim-
bursed for use in Portuguese NHS hospitals; (3) When fingoli-
mod was evaluated by the national HTA Authority, the
selected comparator was natalizumab because natalizumab
was, at that time (Q1, 2012), the only treatment option for
patients with HAD and an insufficient response to first-line
treatments, as well as for patients with rapidly evolving
severe RRMS. The national HTA Authority considered that, for
this population, fingolimod had an added therapeutic value
in comparison to natalizumab due to safety and convenience
aspects. Fingolimod proved cost-effectiveness in a minimiza-
tion cost analysis due the lower treatment costs; and (4)
Both fingolimod and cladribine tablets are oral treatments,
and mode of administration is considered a relevant factor
associated with patient preferences.
Second, the 21-health state model structure is commonly
used in multiple sclerosis assessments but it should be stressed
that the RRMS matrix was based on BCMS data which also
includes patients with SPMS (16%). Although this was not
expected to influence results, it should be addressed as a limita-
tion. Third, after discontinuation, patients were assumed to
switch to Best Supportive Care, with progression and relapse
rates based on disease natural history. Although treatment
switching may occur in clinical practice, this was not considered
in our study, once no clinical data after switch was available.
Moreover, according to the perspective followed, only dir-
ect costs were included. Although it could be argued that
the inclusion of indirect costs would have provided a more
comprehensive analysis, our approach can be potentially
viewed as a conservative one, as it could be assumed that
that the inclusion of indirect costs may demonstrate a stron-
ger dominance of cladribine tablets.
The results from the sensitivity analyses showed that the
cost-effectiveness estimates on cladribine tablets were
robust. The major source of uncertainty was the efficacy of
DMDs beyond clinical trial duration. In line with previous
studies32,33, we considered a reduced effect of DMD beyond
year 2 through the waning effect. Although CLARITY-EXT jus-
tifies the waning effect assumed for cladribine tablets over
4 years, there was no data to support the assumptions
beyond the fourth year. Considering no cladribine tablets
effect after the fourth year impacted the estimated QALYs
(reduced from 0.85 to 0.44).
Recently, Hettle et al.20 published a cost-effectiveness ana-
lysis comparing cladribine tablets with alemtuzumab and
natalizumab in the treatment of relapsing-remitting multiple
sclerosis with HDA in England. The authors found that cladri-
bine tablets was a dominant alternative. However, no com-
parison regarding fingolimod was done. Of note, in this
study the authors used an 11-health state structure that
tracks the disability status of a combined cohort of people
with RRMS and SPMS, instead of the 21-health state model
used in the present case.
NICE appraised the cost-effectiveness of cladribine tablets,
compared to alemtuzumab, daclizumab, fingolimod and
natalizumab, for two separate subgroups of HDA-RRMS
(patients with rapidly evolving severe and sub-optimally
treated), not providing data for the overall HDA-RRMS popu-
lation. Despite the uncertainty in the available data, NICE
concluded that cladribine tablets could be considered a cost-
effective use of National Health Service (NHS) resources in
both subgroups of HDA-RRMS44.
To the best of our knowledge, our study was the first to
assess the cost-effectiveness of cladribine tablets versus fin-
golimod in patients with HDA-RRMS. The results showed that
cladribine tablets were a cost-effective alternative to fingoli-
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Terapêutica (CNFT). Utilizaç~ao de farmacos para o tratamento da




[15] European Medicines Agency. New recommendations to minimise
risks of the rare brain infection PML and a type of skin cancer with
Gilenya: EMA/688187/2015. 18 December 2015. Available from:
https://www.ema.europa.eu/en/news/new-recommendations-min-
imise-risks-rare-brain-infection-pml-type-skin-cancer-gilenya.
[16] Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of
oral cladribine for relapsing multiple sclerosis. N Engl J Med.
2010;362(5):416–426.
[17] Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-
activity-free status in patients with relapsing-remitting multiple
sclerosis treated with cladribine tablets in the CLARITY study: a
post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):
329–337.
[18] Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and effi-
cacy of cladribine tablets in patients with relapsing-remitting
multiple sclerosis: results from the randomized extension trial of
the CLARITY study. Mult Scler. 2018;24(12):1594–1604.
[19] Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost
effectiveness of interferon beta and glatiramer acetate in the
management of multiple sclerosis. Commentary: evaluating dis-
ease modifying treatments in multiple sclerosis. BMJ. 2003;
326(7388):522–522.
[21] Silva EA, Pinto CG, Sampaio C, et al. Orientaç~oes metodologicas
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